Key Takeaways ¢ o ¢ Novo Nordisk said it inked research agreements with two American biotech firms to further develop metabolic-related treatments. The pharmaceutical company is already the market leader in weight-loss drugs through its GLP-1 products including Ozempic and Wegovy. Shares of NVO stock rose more than 4% on the news of the new deals. Shares of Novo Nordisk (NVO), the market leader in weight-loss drugs, jumped more than 4% Thursday after the company said it inked research agreements with two Am ...